Floatz logo

Avalglucosidase Alfa

Glycogen Storage Disease Type II Late Onset

Iris Plugprotein_peptidePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Glycogen Storage Disease Type II Late Onset cohort.

Asset / SponsorPhaseRating
Alglucosidase Alfa
Erasmus Medical Center
Phase 4BBB
Cipaglucosidase Alfa-ATGA
Amicus Therapeutics
Phase 3BB
Miglustat
Amicus Therapeutics
Phase 3B
at2221
Amicus Therapeutics
Phase 3B
Clenbuterol
Duke University
Phase 2CCC

View all 13 →

Same molecule, other indications

Avalglucosidase Alfa is also rated in:

glycogen storage disease IIDormant
A
Indicative ·
82 / 100
View asset →
glycogen storage disease IIDormant
A
Indicative ·
80 / 100
View asset →
pregnancy disorderDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →